TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20713475
Drug: Once-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily budesonide/formoterol (80/4.5 microg x2 inhalations; 160/9 microg daily)
Study: 20713475
Drug: Twice-daily budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily budesonide/formoterol (40/4.5 microg x2 inhalations; 160/18 microg daily)
Study: 7006789
Drug: CCNU (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU (100 mg/m2 p.o. q. 6 weeks)
Study: 7006789
Drug: BCNU (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU (200 mg/m2 p. 6 weeks)
Study: 30767788
Drug: Citrulline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrulline (2 g/day)
Study: 23010339
Drug: Broad-spectrum antibiotic
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotic treatment for 7 days
Study: 18375021
Drug: PCV7 (7-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (7-valent pneumococcal conjugate vaccine) administered > or =7 days before DTaP
Study: 18375021
Drug: PCV7 (7-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (7-valent pneumococcal conjugate vaccine) administered with DTaP
Study: 8872694
Drug: Intravenous glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycopyrrolate
Study: 22763312
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline solution)
Study: 10321444
Drug: Felodipine-metoprolol 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol 5/50 mg o.d. (Logimax)
Study: 2516430
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (control)
Study: 30740658
Drug: Interventions based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions based on gait analysis (including physical therapy, orthotics, spasticity management, and orthopedic surgery)
Study: 28320541
Drug: Ketorolac (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (20 mg)
Study: 20478449
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg)
Study: 25869627
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cycloserine (250, 500, or 1000 mg)
Study: 25869627
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of cycloserine 250 mg BID for 5 days
Study: 19825504
Drug: Duloxetine (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60-120 mg/day)
Study: 8273133
Drug: EPO (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO (all doses)
Study: 2528983
Drug: h alpha
Normalized name: FSH alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: h alpha CGRP infusion (1.5 micrograms min‐1 i.v.)
Study: 26256216
Drug: Nonpharmacologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic therapies (NPTs) provided to nursing home residents, including an online course for physicians and a 1-day seminar for nurses.
Study: 16394797
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and ribavirin treatment in IVDUs
Study: 6329980
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg X 2/die) and sucralfate (1 gr X 2/die)
Study: 323118
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g/day
Study: 6329980
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg/b.i.d.
Study: 24785761
Drug: Striatal dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Striatal dopamine D2/3 receptor availability in obese subjects
Study: 22468623
Drug: Heat-killed Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactobacillus plantarum L-137 (10 mg tablet)
Study: 22468623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (matching tablet)
Study: 17418384
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray, 110 microg once daily
Study: 18517083
Drug: Prednisone, 10
Normalized name: PredniSONE, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 10 mg once daily
Study: 10591389
Drug: High-intensity oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity oral anticoagulants (INR, 2.8-4.8)
Study: 10591389
Drug: Moderate oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate oral anticoagulants (INR, 2-3)
Study: 10591389
Drug: Moderate- to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate- to high-intensity oral anticoagulants (INR, >=2)
Study: 10591389
Drug: Moderate- to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate- to high-intensity oral anticoagulants and aspirin
Study: 10591389
Drug: Low-intensity oral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity oral anticoagulants (INR, <2.0) and aspirin
Study: 12784106
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum 2 mg
Study: 21793279
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg low molecular weight iron-dextran intravenously in two doses (Group A)
Study: 21793279
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg daily for 30 days of iron protein-succinylate (Group B)
Study: 15220185
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity with IL-6 infusion (LO + IL-6)
Study: 15220185
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity without IL-6 infusion (LO)
Study: 7171413
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia with 0.5% bupivacaine plain and morphine sulphate
Study: 29512121
Drug: Intra-articular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ketorolac (5 mg)
Study: 24261316
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg once daily added to gabapentin (maximum 2400 mg daily)
Study: 21309476
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg plain bupivacaine plus 25 mg meperidine (BM25)
Study: 17599306
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (250 mg 4 times per day) for 10 days
Study: 17599306
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (125 mg 4 times per day) for 10 days
Study: 7730907
Drug: Acetaminophen (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10-15 mg/kg/dose)
Study: 2913806
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml of 0.01% intracameral carbachol
Study: 21681118
Drug: Standard-dose gefitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose gefitinib (250 mg daily)
Study: 21681118
Drug: Low-dose gefitinib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose gefitinib (dose reduced due to toxicities)
Study: 18549692
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg daily for 9 days starting on day 2 of menses
Study: 18549692
Drug: Gonadotrophin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin 75 IU intramuscularly daily for 5 days starting on day 3 of menses
Study: 16571154
Drug: High-phenol extra-virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-phenol extra-virgin olive oil (high-EVOO; 592 mg total phenols/kg)
Study: 10858346
Drug: Imiquimod (IQ)
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod (IQ) treatment
Study: 9200356
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg rhSOD intratracheally
Study: 9200356
Drug: rhSOD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhSOD treatment groups
Study: 15277161
Drug: Reduced-fat salad
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-fat salad dressing (6 g canola oil)
Study: 15277161
Drug: Full-fat salad
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-fat salad dressing (28 g canola oil)
Study: 15277161
Drug: Fat-free salad
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-free salad dressing (0 g canola oil)
Study: 10932511
Drug: Norgestrel 0.5
Normalized name: norgestrel 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel 0.5 mg/day
Study: 9059197
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine 0.06 mg kg‐1 at the end of surgery and a second dose 6 h later
Study: 9059197
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received PCA with morphine 0.04 mg kg‐1 i.v.
Study: 1637513
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive treatment
Study: 3732360
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mexiletine
Study: 3732360
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg disopyramide
Study: 12576305
Drug: Ginger pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger pretreatment (1,000 and 2,000 mg)
Study: 12576305
Drug: Intravenous vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vasopressin infusion (0.1 and 0.2 U/min)
Study: 9051704
Drug: Simvastatin at
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin at standard therapeutic doses
Study: 24240575
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1000 IU daily of cholecalciferol combined with 100 mg of elemental calcium administered twice a day)
Study: 19702643
Drug: Total Therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Therapy 2 (TT2)
Study: 18302711
Drug: Total Therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Therapy 3 (TT3) for patients completing TT2 consolidation within 24 months
Study: 12462290
Drug: Fenofibrate 300
Normalized name: fenofibrate 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 300 mg once daily for 8 weeks
Study: 10478810
Drug: Amrinone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (1 mg/kg)
Study: 2675219
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug administered)
Study: 1878318
Drug: Conditioned startle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioned startle reflex augmentation.
Study: 30497077
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no music therapy)
Study: 26494411
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily thoracic radiotherapy (TRT) of 42 Gy in 15 fractions (OD)
Study: 26494411
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily thoracic radiotherapy (TRT) of 45 Gy in 30 fractions (BID)
Study: 24907435
Drug: MP0112 (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0112 (0.04 to 3.6 mg, single intravitreal injection)
Study: 24907435
Drug: MP0112 (0.04-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0112 (0.04-0.4 mg)
Study: 24907435
Drug: MP0112 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0112 (1.0 or 2.0 mg)
Study: 24907435
Drug: MP0112 (higher-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0112 (higher-dose cohorts)
Study: 22294470
Drug: Midostaurin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin (75 mg twice daily for 2 days; 75 mg once on day 3)
Study: 20817247
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL sterile water
Study: 20817247
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL 24% sucrose solution
Study: 12000209
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylpropanolamine (PPA) 75 mg/day
Study: 7638640
Drug: Mitomycin 12
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin 12 mg/m2 given as an intravenous infusion every 6 weeks
Study: 2199599
Drug: Single-dose 500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 500-mg clotrimazole vaginal tablets
Study: 28813414
Drug: Oral synbiotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral synbiotic preparation (Lactobacillus plantarum plus fructooligosaccharide)
Study: 21527122
Drug: Vilazodone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (40 mg/d)
Study: 19056600
Drug: Rye bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye bran flakes containing 44 mg total ARs
Study: 11527284
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment protocol including individual certified nursing assistants (CNAs), in-service training for CNAs, and memory notebooks.
Study: 9815587
Drug: Continuous-infusion vinblastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion vinblastine alone (1.2 mg/m2/day for 4 days or 1.5 mg/m2/day for 5 days)
Study: 28499391
Drug: Chondrosphere® (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondrosphere® (low dose: 3-7 spheroids/cm², medium dose: 10-30 spheroids/cm², high dose: 40-70 spheroids/cm²)
Study: 28499391
Drug: Chondrosphere® (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondrosphere® (all dose levels)
Study: 1319311
Drug: Oral itraconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral itraconazole, 200 mg twice daily
Study: 1319311
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B, 0.6 mg/kg/day (or 0.3 mg/kg/day plus flucytosine, 150 mg/kg/day for some Candida infections)
Study: 6230612
Drug: naproxen-sodium (825
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen-sodium (825 mg)
Study: 6230612
Drug: paracetamol (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol (1,000 mg)
Study: 26925771
Drug: Training in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training in Evidence-Based Medicine (EBM) for 6 months
Study: 18853138
Drug: Bile acids
Normalized name: Conjugated bile acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile acids (5 micromol/l)
Study: 15616226
Drug: Ultralente insulin
Normalized name: ultralente insulin, beef
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralente insulin
Study: 16035063
Drug: Low-dose HCIG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HCIG (75 mg/kg)
Study: 16035063
Drug: High-dose HCIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HCIG (200 mg/kg)
Study: 10417490
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal combined with gastric lavage (25 g charcoal after lavage)
Study: 10417490
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal alone (25 g in 200 ml water)
Study: 10954340
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 ml water)
Study: 18045712
Drug: Flavonoid-rich dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich dark chocolate (Meiji Black Chocolate 45 g, 550 mg cacao polyphenol/day, 200 kcal)
Study: 18045712
Drug: Non-flavonoid white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-flavonoid white chocolate (Meiji White Chocolate 35 g, 0 mg cacao polyphenol/day, 140 kcal)
Study: 11197288
Drug: RAP150 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAP150 group (pantoprazole 40 mg b.i.d., amoxycillin 1 g b.i.d., rifabutin 150 mg o.d.)
Study: 11197288
Drug: RAP300 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAP300 group (pantoprazole 40 mg b.i.d., amoxycillin 1 g b.i.d., rifabutin 300 mg o.d.)
Study: 11197288
Drug: QT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: QT group (pantoprazole 40 mg b.i.d., metronidazole 250 mg t.i.d., bismuth citrate 240 mg b.i.d., tetracycline 500 mg q.i.d.)
Study: 11197288
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy patients
Study: 2673437
Drug: Tetracosactide (TCS)
Normalized name: tetracosactide
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracosactide (TCS) 2 mg
Study: 2673437
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 20 mg
Study: 339647
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg L-dopa
Study: 339647
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg apomorphine
Study: 31094354
Drug: Psychoeducational mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational mobile app plus treatment as usual (TAU)
Study: 9503814
Drug: Isoptin-retard (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoptin-retard (240 mg/day)
Study: 10219807
Drug: Radiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy treatment
Study: 23297639
Drug: Lactulose administration
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose administration (30 ml for 1 week)
Study: 18503891
Drug: Statin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administration (Atorvastatin and Pravastatin)
Study: 22246178
Drug: Statin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin administration
Study: 8277950
Drug: Low sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low sucrose diet with saccharin (12 +/- 4.5 mg/kg/day)
Study: 8011799
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 0.5 mg
Study: 2923936
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 1.0 mg
Study: 2923936
Drug: Standard 1.0‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 1.0‐mg DST
Study: 1934546
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac
Study: 16461878
Drug: Ibuprofen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (5 mg/kg per dose every 8 hours)
Study: 16461878
Drug: Alternating acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating acetaminophen and ibuprofen (every 4 hours)
Study: 8312728
Drug: Inpatient or
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient or residential treatment
Study: 25380193
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 μg inhaled via Respimat® Soft Mist™ Inhaler
Study: 25380193
Drug: Tiotropium (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (2.5 μg or 5 μg)
Study: 9409295
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol combined with progesterone
Study: 8746882
Drug: No hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormonal treatment
Study: 8287641
Drug: II (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: II (insulin infusion only)
Study: 2882967
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (90 adults and 42 adolescents)
Study: 31287236
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of gemfibrozil 600 mg BID with brigatinib 90 mg
Study: 31287236
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of itraconazole 200 mg BID with brigatinib 90 mg
Study: 31287236
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of rifampin 600 mg QD with brigatinib 180 mg
Study: 3582476
Drug: Meptazinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (100 mg)
Study: 6403933
Drug: Morphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (15 mg)
Study: 10491528
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral conjugated equine estrogen (ERT)
Study: 8686714
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (< 3 micrograms/kg/min)